The recent advent of tau PET tracers [92–99], exhibiting a closer anatomical and temporal relationship to clinical symptoms than amyloid PET [100], has been an enabling feature for therapeutic programs targeting tau pathology and promises to provide another important window on how novel potential therapies interact with the Alzheimer’s disease process in the living brain [101]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.